LINKS
ABOUT
SOCIAL
  • Black Twitter Icon

info@agendxbio.com

1400 E. Angela Blvd

South Bend, IN 46617

© 2017 by AgenDx Biosciences, Inc.

OUR TECHNOLOGY

AgenDx is Commercializing a Novel Technology to Bring Accurate and Cost-Effective Molecular Diagnostics to Patient Care

MEET AgenDx

Our Team

Kevin Connors, B.S., M.S., M.B.A. Chief Executive Officer, Co-Founder. Kevin is healthcare inventor, founder, CEO, and investor with more than 26 years experience in medical device and diagnostic start-ups.

Joerg Schreiber, Ph.D.in Biophysics, VP of Research and Development, 30 years experience in Life Science system development and commercialization in Executive positions and as consultant.

George Spohrer, COO with 30 years of management consulting in Manufacturing and Systems Integration.

Chris Wynne, CFO with 35 years in accounting and finance. CFO at medium and large private companies.

Ben Miller, M.B.A. Founder,  Entrepreneur with 8 years experience in Manufacturing and Services.

Zdenek Slouka, Ph.D. Scientist, Inventor. Zdenek is Research Assistant Professor at the University of Chemistry and Technology Prague with experience in electrochemisty, electrokinetics, microfluidics and microfabrication.

Hseuh-Chia Chang, Ph.D. Director of the Center for Microfluidics & Medical Diagnostics at Notre Dame.


Satyajyoti Senapati, Ph.D. Scientist, Inventor. Satyajyoti is a Post Doctoral Research Associate experienced in chemical engineering and biosensing. He is currently a Research Assistant Professor at Notre Dame.

Sharon Stack, Ph.D. Director of the Harper Cancer Research Institute. Sharon was most recently Vice-Chair for Research at the University of Missouri School of Medicine.


Reginald Hill, Ph.D. Associate Professor of Cancer Biology at the Harper Cancer Research Institute. Reggie was most recently Postdoctoral Fellow, in Medical and Molecular Pharmacology at UCLA

Management

Advisors

GET IN TOUCH

REQUEST INFO

 
 
 
 
 

AgenDx is a startup currently located inside the IDEA Center at the University of Notre Dame http://ideacenter.nd.edu/

Latest News:

February 5, 2018 - AgenDx Biosciences Inc., an early stage molecular diagnostics company focused on improving the treatment of patients with pancreatic cancer, today announced that it closed its seed financing, raising a total of $1.525 million.